



That Which Is Claimed Is:

1. A compound having the structure represented by the formula:



- 5 wherein Cy represents a 5 or 6 member aromatic ring, B' represents an
alkylene bridging moiety, Q is (CH₂)_m, Q' is (CH₂)_p, and Q'' is (CH₂)_q where m
is 1, 2, 3 or 4, p is 0, 1, 2 or 3, and q is 0, 1 or 2, and the values of m, p and q
are selected such that the azabicyclic ring shown in the structure contains 6,
7, 8 or 9 members, Z_j represents a non-hydrogen substituent group, j is an
10 integer from 0 to 5, Z' represent hydrogen or lower alkyl, the dotted lines in the
structure signify bonds that can be either carbon-carbon single bonds or
carbon-carbon double bonds subject to the provision that only one dotted line
represents a carbon-carbon double bond.


- 15 2. The compound of Claim 1 wherein Cy is:



wherein A and A' individually are either hydrogen or suitable non-hydrogen
substituent species having a sigma m value between about -0.3 and about
0.75.

20

3. The compound of Claim 1 wherein Cy is



- 5 X, X' and X'' are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about -0.3 and about 0.75, A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about -0.3 and about 0.75.

10

4. The compound of Claim 3 wherein X'' is nitrogen.

5. The compound of Claim 3 wherein X'' is selected from the group consisting of CNO₂, CNH₂, CNHCH₃ and CN(CH₃)₂.

15

6. The compound of Claim 3 wherein X' and X'' are nitrogen.

7. The compound of Claim 3 wherein Cy represents a 3-pyridyl moiety.

20

8. The compound of Claim 1 selected from the group consisting of:
(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)isoxazole and
(E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)-3-methylisoxazole.

30


9. The compound of Claim 1 selected from the group consisting of:
- (E)- and (Z)-2-(2-(3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-ethoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
5 (E)- and (Z)-2-(2-(5-isopropoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isobutoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-phenoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-benzyloxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxymethyl-3-pyridyl)ethenyl)-7-
10 azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-phenyl-3-pyridyl) ethenyl)-7-
azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-hydroxy-3-pyridyl)ethenyl)-7-
azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-pyrimidinyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane
15 (E)- and (Z)-6-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane and
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 9-azabicyclo[4.2.1]nonane.

10. The compound of Claim 1 selected from the group consisting of:
- 2-(2-(3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
20 2-(2-(5-methoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-ethoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isopropoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isobutoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-phenoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
25 2-(2-(5-benzyloxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxymethyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-phenyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-hydroxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-pyrimidinyl)ethynyl)-7-azabicyclo[2.2.1]heptane
30 2-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane
6-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane and
2-(2-(3-pyridyl)ethynyl)- 9-azabicyclo[4.2.1]nonane.

11. The compound of Claim 1 wherein m is 1, 2 or 3.
12. The compound of Claim 1 wherein p is 0, 1 or 2.
- 5 13. The compound of Claim 1 wherein q is 0 or 1.
14. The compound of Claim 1 wherein j is 0 or 1.
- 10 15. The compound of Claim 1 wherein B' is ethylenic.
16. The compound of Claim 1 wherein B' is acetylenic.
17. The compound of Claim 1 wherein B' is a two carbon atom
15 bridging species.
18. The compound of Claim 1 wherein j is 0; Z' is hydrogen or lower
alkyl; m is 1, 2 or 3; q is 0 or 1; p is 1 or 2; and each of E' and E'' is hydrogen.
- 20 19. The compound of Claim 18 wherein the sum of m and q is 3 or
less.
20. The compound of Claim 1 wherein Cy is 3-pyridyl, unsubstituted
or substituted in the 5 and/or 6 position(s), 5-pyrimidinyl unsubstituted or
25 substituted in the 2 position, or 3- or 5-isoxazolyl unsubstituted or substituted
in the 4 and/or 5 and 3 and/or 4 positions respectively.

21. A method for treating a disorder characterized by an alternation in normal neurotransmitter release, the method comprising administering an effective amount of a compound having the structure represented by the formula:

5




wherein Cy represents a 5 or 6 member aromatic ring, B' represents an alkylene bridging moiety, Q is $(CH_2)_m$, Q' is $(CH_2)_p$, and Q'' is $(CH_2)_q$ where m is 1, 2, 3 or 4, p is 0, 1, 2 or 3, and q is 0, 1 or 2, and the values of m, p and q are selected such that the azabicyclic ring shown in the structure contains 6, 7, 8 or 9 members, Z_j represents a non-hydrogen substituent group, j is an integer from 0 to 5, Z' represent hydrogen or lower alkyl, the dotted lines in the structure signify bonds that can be either carbon-carbon single bonds or carbon-carbon double bonds subject to the provision that only one dotted line represents a carbon-carbon double bond.

10

15


22. The method of Claim 21 whereby Cy is:



20

wherein A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about -0.3 and about 0.75.

23. The method of Claim 21 whereby Cy is



5 X, X' and X'' are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about -0.3 and about 0.75, A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about -0.3 and about 0.75.

10

24. The method of Claim 23 whereby X'' is nitrogen.

25. The method of Claim 23 whereby X'' is selected from the group consisting of CNO₂, CNH₂, CNHCH₃ and CN(CH₃)₂.

15

26. The method of Claim 23 whereby X' and X'' are nitrogen.

27. The method of Claim 23 whereby Cy represents a 3-pyridyl moiety.

20

28. The method of Claim 21 whereby the compound is selected from the group consisting of:

(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)-3-methylisoxazole

25 (E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)-3-methylisoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)-3-methylisoxazole

(E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)isoxazole and

30 (E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)-3-methylisoxazole.

29. The method of Claim 21 whereby the compound is selected from the group consisting of:

- (E)- and (Z)-2-(2-(3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
5 (E)- and (Z)-2-(2-(5-methoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-ethoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isopropoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isobutoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-phenoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
10 (E)- and (Z)-2-(2-(5-benzyloxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxymethyl-3-pyridyl)ethenyl)-7-
azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-phenyl-3-pyridyl) ethenyl)-7-
azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-hydroxy-3-pyridyl)ethenyl)-7-
azabicyclo[2.2.1]heptane
15 (E)- and (Z)-2-(2-(5-pyrimidinyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane
(E)- and (Z)-6-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane and
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 9-azabicyclo[4.2.1]nonane.

20 30. The method of Claim 21 whereby the compound is selected from the group consisting of:

- 2-(2-(3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-ethoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
25 2-(2-(5-isopropoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isobutoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-phenoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-benzyloxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxymethyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
30 2-(2-(5-phenyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-hydroxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-pyrimidinyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane
6-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane and
2-(2-(3-pyridyl)ethynyl)- 9-azabicyclo[4.2.1]nonane.

5 31. The method of Claim 21 whereby m is 1, 2 or 3.

32. The method of Claim 21 whereby p is 0, 1 or 2.

33. The method of Claim 21 whereby q is 0 or 1.

10

34. The method of Claim 21 whereby j is 0 or 1.

35. The method of Claim 21 whereby B' is ethylenic.

15

36. The method of Claim 21 whereby B' is acetylenic.

37. The method of Claim 21 whereby B' is a two carbon atom
bridging species.

20

38. The method of Claim 21 whereby j is 0; Z' is hydrogen or lower
alkyl; m is 1, 2 or 3; q is 0 or 1; p is 1 or 2; and each of E' and E'' is hydrogen.


39. The method of Claim 38 whereby the sum of m and q is 3 or
less.

25

40. The method of Claim 21 whereby Cy is 3-pyridyl, unsubstituted
or substituted in the 5 and/or 6 position(s), 5-pyrimidinyl unsubstituted or
substituted in the 2 position, or 3- or 5-isoxazolyl unsubstituted or substituted
in the 4 and/or 5 and 3 and/or 4 positions respectively.


30

41. A pharmaceutical composition comprising an effective amount of a compound having the structure represented by the formula:




5 wherein Cy represents a 5 or 6 member aromatic ring, B' represents an
alkylene bridging moiety, Q is $(CH_2)_m$, Q' is $(CH_2)_p$, and Q'' is $(CH_2)_q$ where m
is 1, 2, 3 or 4, p is 0, 1, 2 or 3, and q is 0, 1 or 2, and the values of m, p and q
are selected such that the azabicyclic ring shown in the structure contains 6,
7, 8 or 9 members, Z_j represents a non-hydrogen substituent group, j is an
10 integer from 0 to 5, Z' represent hydrogen or lower alkyl, the dotted lines in the
structure signify bonds that can be either carbon-carbon single bonds or
carbon-carbon double bonds subject to the provision that only one dotted line
represents a carbon-carbon double bond.

15 42. The pharmaceutical composition of Claim 41 wherein Cy is:



20 wherein A and A' individually are either hydrogen or suitable non-hydrogen
substituent species having a sigma m value between about -0.3 and about
0.75.

43. The pharmaceutical composition of Claim 41 wherein Cy is



5

X, X' and X'' are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about -0.3 and about 0.75, A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value

10 between about -0.3 and about 0.75.

44. The pharmaceutical composition of Claim 43 wherein X'' is nitrogen.

15

45. The pharmaceutical composition of Claim 43 wherein X'' is selected from the group consisting of CNO₂, CNH₂, CNHCH₃ and CN(CH₃)₂.

46. The pharmaceutical composition of Claim 43 wherein X' and X'' are nitrogen.

20

47. The pharmaceutical composition of Claim 43 wherein Cy represents a 3-pyridyl moiety.

48. The pharmaceutical composition of Claim 41 wherein the compound is selected from the group consisting of:

25

(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)-3-methylisoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)-3-methylisoxazole

30

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)isoxazole and
(E)- and (Z)-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)-3-methylisoxazole.

5 49. The pharmaceutical composition of Claim 41 wherein the
compound is selected from the group consisting of:

(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-ethoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
10 (E)- and (Z)-2-(2-(5-isopropoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isobutoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-phenoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-benzyloxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxymethyl-3-pyridyl)ethenyl)-7-
15 azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-phenyl-3-pyridyl) ethenyl)-7-
azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-hydroxy-3-pyridyl)ethenyl)-7-
azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-pyrimidinyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane
20 (E)- and (Z)-6-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane and
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 9-azabicyclo[4.2.1]nonane.

50. The pharmaceutical composition of Claim 41 wherein the
compound is selected from the group consisting of:

25 2-(2-(3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-ethoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isopropoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isobutoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
30 2-(2-(5-phenoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-benzyloxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxymethyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-phenyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-hydroxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-pyrimidinyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane
5 6-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane and
2-(2-(3-pyridyl)ethynyl)- 9-azabicyclo[4.2.1]nonane.

51. The pharmaceutical composition of Claim 41 wherein m is 1, 2
or 3.

10 52. The pharmaceutical composition of Claim 41 wherein p is 0, 1 or
2.

53. The pharmaceutical composition of Claim 41 wherein q is 0 or 1.

15 54. The pharmaceutical composition of Claim 41 wherein j is 0 or 1.

55. The pharmaceutical composition of Claim 41 wherein B' is
ethylenic.

20 66. The pharmaceutical composition of Claim 41 wherein B' is
acetylenic.

25 67. The pharmaceutical composition of Claim 41 wherein B' is a two
carbon atom bridging species.

68. The pharmaceutical composition of Claim 41 wherein j is 0; Z' is
hydrogen or lower alkyl; m is 1, 2 or 3; q is 0 or 1; p is 1 or 2; and each of E'
and E'' is hydrogen.

30 69. The pharmaceutical composition of Claim 68 wherein the sum of
m and q is 3 or less.

70. The pharmaceutical composition of Claim 41 wherein Cy is 3-
pyridy, unsubstituted or substituted in the 5 and/or 6 position(s), 5-pyrimidinyl
unsubstituted or substituted in the 2 position, or 3- or 5-isoxazolyl
5 unsubstituted or substituted in the 4 and/or 5 and 3 and/or 4 positions
respectively.

10